# Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance

Source: https://onco.cc/trials/nct00582166/  
OnCo record `nct00582166` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ibritumomab tiuxetan and Rituximab in Non-Hodgkin lymphoma, run by University of Wisconsin, Madison, recorded as terminated on the registry.

## Summary

Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance is a phase 2 interventional study registered as NCT00582166 by University of Wisconsin, Madison, with 18 participants recorded, started 2005-01-25 and due to reach its primary completion in 2013-03. Interventions recorded: Ibritumomab Tiuxetan (Zevalin) + Rituximab. Conditions recorded: Non-Hodgkin's Lymphoma.

Linked to the drug Ibritumomab tiuxetan because the registry names it among its interventions and Non-Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00582166
- Phase: 2
- Setting: Ibritumomab Tiuxetan Plus Rituximab as Initial Therapy for Patients With High Tumor Burden, Indolent Histology Non-Hodgkin's Lymphoma
- Sponsor: University of Wisconsin, Madison
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT00582166: https://clinicaltrials.gov/study/NCT00582166

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Ibritumomab tiuxetan](https://onco.cc/drugs/ibritumomab-tiuxetan/), [Rituximab](https://onco.cc/drugs/rituximab/)

---
JSON: https://onco.cc/api/v1/entities/nct00582166.json